阴道、肠道或膀胱子宫内膜异位症患者诊断延迟时间延长:一项观察性研究
这项在丹麦三级子宫内膜异位症中心开展的观察性队列研究纳入129例接受手术的患者,比较病变累及阴道、肠道、直肠阴道隔或膀胱(eVIRB)者与非eVIRB者的诊断延迟和症状。eVIRB组中位诊断延迟9年,显著长于非eVIRB组的2年(P=0.005);诊断延迟超过5年时eVIRB的比值比为5倍(95%CI 2.18-11.61,P<0.001)。
要点
- eVIRB组中位诊断延迟9年,非eVIRB组2年,差异显著(P=0.005)。
- 诊断延迟超过5年者发生eVIRB的比值比为5倍(95%CI 2.18-11.61,P<0.001)。
- eVIRB组报告症状起病更早,需卧床并使用止痛药的严重痛经差异显著。
核心结论
- 晚期子宫内膜异位症患者诊断延迟显著更长、症状起病更早且经期疼痛更剧烈。
- 本研究在调整激素使用总年限和手术时年龄后,首次描述晚期子宫内膜异位症与诊断延迟延长之间的关联。
- 本研究描述的是诊断延迟延长与晚期疾病之间的关联,而非因果关系。
研究设计与样本
- 观察性队列研究,纳入129例接受子宫内膜异位症手术的患者,研究历时3年,首例手术于2019年11月。
- 患者填写回顾性问卷,手术医生描述术中所见。
- 患者在丹麦一家三级子宫内膜异位症中心接受手术,主要针对中度至重度子宫内膜异位症。
主要发现
- 总体中位诊断延迟为5年。
- eVIRB组(n=75)中位诊断延迟为9年,非eVIRB组(n=54)为2年,差异显著(P=0.005)。
- 诊断延迟超过5年时,发生eVIRB的比值比为5倍(95%CI 2.18-11.61,P<0.001)。
- eVIRB组报告子宫内膜异位症症状起病显著更早。
- 两组均报告多种疼痛症状,仅在需卧床并使用止痛药的严重痛经上差异显著;eVIRB组激素使用时间显著更长,因盆腔痛更规律使用止痛药。
局限性
- 回顾性数据可能受回忆偏倚影响。
- 本研究描述的是诊断延迟延长与晚期疾病之间的关联,而非因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do the diagnostic delay and symptoms differ between endometriosis patients with advanced disease, defined as endometriosis involving the vagina, intestine, rectovaginal septum, or bladder (eVIRB), compared to patients without endometriosis in these locations (non-eVIRB)? SUMMARY ANSWER: Patients with advanced endometriosis had a significantly longer diagnostic delay, an earlier onset of symptoms, and more intense pain during menstruation. WHAT IS KNOWN ALREADY: Endometriosis patients often experience years of symptoms before diagnosis. Whether there is an association between the length of this diagnostic delay and advanced disease remains unclear. Confirming such an association would underscore the importance of early diagnosis to ensure appropriate treatment, which may reduce the risk of irreversible organ damage and high-risk surgery for patients. STUDY DESIGN, SIZE, DURATION: This is an observational cohort study of 129 patients undergoing endometriosis surgery conducted over a 3-year period. The first patient was operated on in November 2019. All patients reported retrospective questionnaire data, and surgeons described surgical findings. PARTICIPANTS/MATERIALS, SETTING, METHODS: The patients were operated on for predominantly moderate to severe endometriosis at a Tertiary Endometriosis Centre in Denmark. The diagnostic delay was calculated from questionnaire data and related to intraoperative findings. Selected symptoms were compared. MAIN RESULTS AND THE ROLE OF CHANCE: The median diagnostic delay was 5 years. However, the patients with eVIRB (n = 75) experienced a significantly longer median diagnostic delay of 9 years compared to non-eVIRB patients (n = 54), who had a median delay of only 2 years (P = 0.005). The odds ratio of having eVIRB was 5-fold (95% CI 2.18-11.61, P < 0.001) increased if the diagnostic delay exceeded 5 years, and they reported a significantly earlier onset of endometriosis symptoms. Both groups reported numerous pain symptoms, with a significant difference observed only in responses regarding severe period cramps requiring bed rest and use of painkillers. The eVIRB group had used hormones significantly longer and had taken painkillers more regularly due to pelvic pain. LIMITATIONS, REASONS FOR CAUTION: The retrospective data may be affected by recall bias. This study describes associations between a prolonged diagnostic delay and advanced disease, not causality. WIDER IMPLICATIONS OF THE FINDINGS: This study is the first to describe an association between advanced endometriosis and a prolonged diagnostic delay after adjusting for total years of hormonal use and age at surgery. Future research should concentrate on strategies to achieve earlier diagnosis for patients presenting with this advanced form of the disease, given the potential for severe complications. STUDY FUNDING/COMPETING INTEREST(S): Ferring Pharmaceuticals (MiHSN01) and partial funding from The European Union's Horizon 2020 research and innovation programme (No. 101017562). None of the funders was involved in the study design, data collection, analysis, writing of this paper, or the decision to submit it for publication. H.S.N. reports speakers' fees from Ferring Pharmaceuticals, Merck Denmark A/S, IBSA Nordic, AstraZeneca, Cook Medical, Gedeon Richter, and Novo Nordisk outside the submitted work. No other conflicts are reported. TRIAL REGISTRATION NUMBER: N/A.
引用
- Madsen ME, Hartwell D, Kähler LKA, et al. Patients with endometriosis in the vagina, bowel, or bladder experience a prolonged diagnostic delay: an observational study. Hum Reprod. 2025. PMID: 40127638. doi:10.1093/humrep/deaf046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。